RXDX-106 / Daiichi Sankyo, Roche  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RXDX-106 / Roche
TITAN, NCT03454243: Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Terminated
1
1
US
RXDX-106
Hoffmann-La Roche
Advanced or Metastatic Solid Tumors
06/18
06/18

Download Options